Short answer
GRAIL, Inc. (GRAL) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
GRAIL, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 5, 2026
- Detailed financial results and management commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue rose 26% to $44.7M; Galleri revenue increased 24% to $42.6M on test volume growth of 35% to over 61,000
- First-half Galleri revenue reached $82.5M, up 30%, while volume exceeded 117,000, up 42%
- Persistent losses: net loss $110.2M and adjusted EBITDA $(90.3)M, despite adjusted gross profit increasing 34% to $21.6M
- Liquidity remained substantial at $861.6M, following completed $110M equity financing with Samsung and potential Asian commercialization
- FDA advisory committee anticipated in fall for Galleri’s PMA application, creating a major regulatory catalyst while the test remains unapproved by FDA
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GRAIL, Inc. 8-K filings
Get the next GRAL 8-K as it lands
Follow GRAL for push alerts, or ask the research agent what this filing means.